Skip to content
Biodatica
Start free

Miltenyi Biomedicine GmbH

Augsburg, Bavaria

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

5w agoTrial registeredJun 10, 2026Source filing (opens the source filing in a new tab)

Momentum

75no change

Momentum 75 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Aug 1, 2025

    Hodgkin Lymphoma · NOT_YET_RECRUITING · sponsor: University of Cologne · Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

    ClinicalTrials.gov · NCT06045195 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Aug 18, 2021

    Diffuse Large B-cell Lymphoma · RECRUITING · sponsor: Miltenyi Biomedicine GmbH · Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

    ClinicalTrials.gov · NCT04844866 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Feb 25, 2019

    B-cell Non Hodgkin Lymphoma · COMPLETED · sponsor: Miltenyi Biomedicine GmbH · Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

    ClinicalTrials.gov · NCT03870945 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources